Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report.
作者： Gianluca Trifirò , Ilaria Marcianò , Paola M. Cutroneo , Edoardo Spina , Eliana Mirabelli
关键词:
摘要: In November 2012, a 72-year old patient was diagnosed with left eye wet age-related macular degeneration. The received three monthly intravitreal injections of ranibizumab, complete resolution retinal haemorrhage and oedema reinstatement visual acuity. May 2015, symptomatic relapse detected. again treated overall 6 till the end February 2016. 2016, complained hand resting tremor, bradykinesia postural rigidity head trunk. A diagnosis clinically established PD made based on new criteria Movement Disorders Society. Single Photon Emission Computerized Tomography Dopamine Transporter 123I-ioflupane, documented low DAT uptake mostly in right striatum. Due to protective role vascular endothelial growth factor (VEGF) dopaminergic neurons, intensive anti-VEGF agent ranibizumab may have played as an additional risk accelerating neurodegeneration process related onset clinical signs symptoms.
frontiersin.org
sci-hub.se 参考文章(43)
Seppo Ylä-Herttuala, Tuomas T. Rissanen, Ismo Vajanto, Juha Hartikainen, Vascular Endothelial Growth Factors Journal of the American College of Cardiology. ,vol. 49, pp. 1015- 1026 ,(2007) , 10.1016/J.JACC.2006.09.053
P S Whitton, Inflammation as a causative factor in the aetiology of Parkinson's disease. British Journal of Pharmacology. ,vol. 150, pp. 963- 976 ,(2007) , 10.1038/SJ.BJP.0707167
Behrooz K. Shamloo, Pankdeep Chhabra, Andrew N. Freedman, Arnold Potosky, Jennifer Malin, Sheila Weiss Smith, Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. Drug Safety. ,vol. 35, pp. 507- 518 ,(2012) , 10.2165/11597600-000000000-00000
Ivan Bodis-Wollner, Shahnaz Miri, Sofya Glazman, Venturing into the no‐man's land of the retina in Parkinson's disease Movement Disorders. ,vol. 29, pp. 15- 22 ,(2014) , 10.1002/MDS.25741
Paulus T.V.M. de Jong, Mechanisms of disease: Age-related macular degeneration The New England Journal of Medicine. ,vol. 355, pp. 1474- 1485 ,(2006) , 10.1056/NEJMRA062326
Scott Miners, Hayley Moulding, Rohan de Silva, Seth Love, Reduced vascular endothelial growth factor and capillary density in the occipital cortex in dementia with Lewy bodies. Brain Pathology. ,vol. 24, pp. 334- 343 ,(2014) , 10.1111/BPA.12130
Murray H. Brilliant, Kamyar Vaziri, Thomas B. Connor, Stephen G. Schwartz, Joseph J. Carroll, Catherine A. McCarty, Steven J. Schrodi, Scott J. Hebbring, Krishna S. Kishor, Harry W. Flynn, Andrew A. Moshfeghi, Darius M. Moshfeghi, M. Elizabeth Fini, Brian S. McKay, Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration The American Journal of Medicine. ,vol. 129, pp. 292- 298 ,(2016) , 10.1016/J.AMJMED.2015.10.015
Janette M. Krum, Nina Mani, Jeffrey M. Rosenstein, Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury Experimental Neurology. ,vol. 212, pp. 108- 117 ,(2008) , 10.1016/J.EXPNEUROL.2008.03.019
M. Piltonen, A. Planken, O. Leskelä, T.T. Myöhänen, A.-L. Hänninen, P. Auvinen, K. Alitalo, J.-O. Andressoo, M. Saarma, P.T. Männistö, Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo. Neuroscience. ,vol. 192, pp. 550- 563 ,(2011) , 10.1016/J.NEUROSCIENCE.2011.06.084
X. Yue, D.J. Hariri, B. Caballero, S. Zhang, M.J. Bartlett, O. Kaut, D.W. Mount, U. Wüllner, S.J. Sherman, T. Falk, Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease. Neuroscience. ,vol. 258, pp. 385- 400 ,(2014) , 10.1016/J.NEUROSCIENCE.2013.11.038